Navigation Links
Sinovac Reports Unaudited First Quarter 2010 Financial Results
Date:5/13/2010

BEIJING, May 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

    First Quarter 2010 Financial Highlights (comparisons to First Quarter 2009)
    -- Sales for the first quarter decreased 32% to $4.4 million
    -- Operating loss for the first quarter was $865,000, compared to
       operating income of $646,000
    -- Net loss attributable to shareholders for the first quarter was
       $307,000, with loss per diluted share of $0.01
    -- Cash and cash equivalents at March 31, 2010 increased to $118.9 million,
       reflecting the closing of the common share public offering in February
       2010


    Business Highlights
    -- In April 2010, Sinovac's joint venture, Sinovac Dalian, submitted an
       application to China's State Food and Drug Administration (SFDA) to
       commence human clinical trials for its mumps vaccine. The proprietary
       mumps vaccine developed by Sinovac Dalian represents not only the first
       live attenuated vaccine for which Sinovac Dalian has filed a clinical
       trial application, but also the first candidate from the joint
       venture's pipeline for which a clinical trial application has been
       submitted to and accepted by the SFDA since the formation of the joint
       venture in January 2010.
    -- In May 2010, Sinovac Biotech, through its wholly owned subsidiary
       Sinovac Biotech (Hong Kong) Ltd, made an initial cash contribution of
       60 million RMB, or approximately $8.8 million, to Sinovac Dalian, the
       Company's 30%-owned joint venture 
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
2. Sinovac Announces Upsizing and Pricing of Common Share Offering
3. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
4. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
5. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
6. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
7. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
8. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
9. Sinovac to Present at 2009 UBS Global Life Sciences Conference
10. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
11. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Japan , April 16, 2015  Center ... University and Takeda Pharmaceutical Company Limited (Takeda) announced ... clinical applications of induced pluripotent stem cells in ... disorders and cancer immunotherapy. The "Takeda-CiRA Joint Program ... expedite multiple research projects for drug discovery and ...
(Date:4/16/2015)... April 16, 2015 Proove Biosciences ... Buzz of BIO Contest for the 2015 BIO ... the 2015 BIO International Convention will take place June ... During the Buzz of BIO contest, industry leaders will ... present at the conference. The community voting period began ...
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... China, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Inc., (OTC ... traditional Chinese medicine (TCM) based in Chengdu,China, today ... the Board of,Directors, will host a conference call ... results., The conference call will take place ...
... 7 Dilon Technologies, makers of,a gamma imaging system ... Moussa to the position of President and Chief Executive,Officer., ... the medical device industry,having held a number of senior ... a health care corporation he ran as,CEO for a ...
... 7 MedImmune today announced,that it has strengthened ... affairs with three key promotions and has also ... Kiener, D. Phil. has been appointed,to executive vice ... organization development, HR; and Eileen Valenta to vice ...
Cached Biology Technology:Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST 2Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ' ... Major Weapon in the Battle Against Cancer' 2MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 2MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 3MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 4
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... for the first time a surprising and unexpected plasticity ... cells are made in early development. Scientists ... type of gene that controls cell fate by regulating ... stem and progenitor cells in blood forming tissues to ...
... (August 2, 2012) Autism Speaks, the world,s ... its expanded collaboration with Sigma Advanced Genetic Engineering ... develop the first rat models with modified autism ... autism research. Expansion of the collaboration follows ...
... in 10 children suffers from asthma but the potential ... known. Cincinnati-based researchers now report new evidence that exposure ... a direct link to asthma development during childhood. ... Penicillium variabileare typically found growing in water-damaged homes, putting ...
Cached Biology News:Embryonic blood vessels that make blood stem cells can also make beating heart muscles 2Embryonic blood vessels that make blood stem cells can also make beating heart muscles 3Autism Speaks and SAGE® Labs develop rat models for translational autism research 2Autism Speaks and SAGE® Labs develop rat models for translational autism research 3Infants exposed to specific molds have higher asthma risk 2
IHC Detection Kit (Broad Spectrum AEC)....
...
...
... to L1 Cell Adhesion Molecule ... in Xq28, is involved in three distinct ... of Sylvius); 2) MASA (mental retardation, aphasia, ... (spastic paraplegia). Immunogen: ...
Biology Products: